title: Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis.
abstract: OBJECTIVE
  Management of chronic refractory pouchitis, a common cause for pouch failure with pouch resection or diversion, is often challenging. The aim of this study was to assess the efficacy and safety of a combination therapy of ciprofloxacin and tinidazole in patients with chronic refractory pouchitis compared with mesalamine therapy.
  
  
  METHODS
  Sixteen consecutive ulcerative colitis patients with chronic refractory pouchitis (disease>4 weeks and failure to respond to>4 weeks of single-antibiotic therapy) were treated with a four-week course of ciprofloxacin 1 g/day and tinidazole 15 mg/kg/day. A historic cohort of ten consecutive patients with chronic refractory pouchitis treated with oral (4 g/day), enema (8 g/day), or suppository (1 g/day) mesalamine served as controls. The Pouchitis Disease Activity Index, clinical remission, clinical response, the Cleveland Global Quality of Life, the Irritable Bowel Syndrome-Quality of Life, and the Short Inflammatory Bowel Disease Questionnaires scores were calculated before and after therapy and compared between the two treatment groups.
  
  
  RESULTS
  Patients taking ciprofloxacin and tinidazole had a significant reduction in the total Pouchitis Disease Activity Index scores and subscores and a significant improvement in quality-of-life scores (P < 0.002). For patients in the mesalamine group, there was a significant reduction in the total Pouchitis Disease Activity Index scores only. Patients in the antibiotic group had a greater reduction in the total Pouchitis Disease Activity Index scores and a greater improvement in the quality-of-life scores than those in the mesalamine group (P <or= 0.03). The rate of clinical remission and clinical response for the antibiotic group was 87.5 percent and 87.5 percent, respectively, and for the mesalamine group it was 50 percent and 50 percent, respectively (P = 0.069). Two patients in the antibiotic group (peripheral neuropathy and dysgeusia) developed adverse effects.
  
  
  CONCLUSIONS
  Combination therapy with ciprofloxacin and tinidazole was generally well tolerated and was effective in treating patients with chronic refractory pouchitis.
authors.affiliation: Department of Gastroenterology/Hepatology, Center for Inflammatory Bowel Disease, Cleveland Clinic, Cleveland, Ohio 44195, USA. shenb@ccf.org
authors.forename: Bo
authors.initials: B
authors.lastname: Shen
authors.forename: Victor W
authors.initials: VW
authors.lastname: Fazio
authors.forename: Feza H
authors.initials: FH
authors.lastname: Remzi
authors.forename: Ana E
authors.initials: AE
authors.lastname: Bennett
authors.forename: Rocio
authors.initials: R
authors.lastname: Lopez
authors.forename: Aaron
authors.initials: A
authors.lastname: Brzezinski
authors.forename: Ioannis
authors.initials: I
authors.lastname: Oikonomou
authors.forename: Kerry K
authors.initials: KK
authors.lastname: Sherman
authors.forename: Bret A
authors.initials: BA
authors.lastname: Lashner
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D002939:Ciprofloxacin / Q000008:administration & dosage*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019449:Pouchitis / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D014011:Tinidazole / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D014011:Tinidazole; D002939:Ciprofloxacin